CALR mutation profile in Irish patients with myeloproliferative neoplasms

详细信息    查看全文

• 作者：Karl Haslam^a ; Eibhlin Conneally^b ; Catherine M. Flynn^b ; Mary R. Cahill^c ; Oonagh Gilligan^c ; Derville O&rsquo ; Shea^c ; Stephen E. Langabeer^a ; ^{slangabeer@stjames.ie" class="auth_mail" title="E-mail the corresponding author}
• 关键词：CALR ; Essential thrombocythemia ; JAK2 ; Myeloproliferative neoplasm ; Primary myelofibrosis
• 刊名：Hematology/Oncology and Stem Cell Therapy
• 出版年：2016
• 出版时间：September 2016
• 年：2016
• 卷：9
• 期：3
• 页码：112-115
• 全文大小：316 K

文摘

Insertion and/or deletion mutations of the CALR gene have recently been demonstrated to be the second most common driver mutations in the myeloproliferative neoplasms (MPNs) of essential thrombocythemia (ET) and primary myelofibrosis (PMF). Given the diagnostic and emerging prognostic significance of these mutations, in addition to the geographical heterogeneity reported, the incidence of CALR mutations was determined in an Irish cohort of patients with MPNs with a view to incorporate this analysis into a prospective screening program. A series of 202 patients with known or suspected ET and PMF were screened for the presence of CALR mutations. CALR mutations were detected in 58 patients. Type 1 and Type 1-like deletion mutations were the most common (n = 40) followed by Type 2 and Type 2-like insertion mutations (n = 17). The CALR mutation profile in Irish ET and PMF patients appears similar to that in other European populations. Establishment of this mutational profile allows the introduction of a rational, molecular diagnostic algorithm in cases of suspected ET and PMF that will improve clinical management.